Market Overview

Merck Is Up 40% In 2018: What's Driving The Rally?

Share:
Merck Is Up 40% In 2018: What's Driving The Rally?
Related MRK
The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering
Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details
Merck announces executive appointments (Seeking Alpha)

Large-cap pharma stocks have had a decent 2018, with strong earnings momentum primarily responsible for the optimism in the space. Tax cuts enabled companies to augment cash reserves, giving them flexibility to pursue inorganic growth to enrich product pipelines.

Here's how large-cap pharmas have performed year-to-date through Nov. 28. 

large-cap_pharma11_2_0.png

The top performer so far this year has been Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK), with shares hitting a seven-year high. 

Merck's Revenue Sources 

Merck reports revenue in the pharmaceutical, animal health livestock, companion animal and other segments. 

In Merck's recent Q3 print, the pharmaceutical segment earned about $9.66 billion, or 90 percent of the company's total revenue of $10.79 billion.

The revenue breakdown for Merck's four top-selling products is as follows:  

  • Keytruda: 18 percent.
  • The diabetes franchise comprising Januvia and Janumet: 14 percent.
  • The HPV-related cancer vaccines Gardasil/Gardasil 9: 10 percent.
  • Proquad, MMR II and Varivax (MMR and Varicella vaccines): 5 percent.
  • These products accounted for roughly half of Merck's total revenue in the quarter. 

Citing strong confidence in its pipeline, long-term revenue growth, cash flow projections and overall balance sheet strength, Merck raised its quarterly dividend by about 15 percent to 55 cents per share and announced a $10-billion stock buyback plan.

A Wonder Drug Called Keytruda

Keytruda, chemically pembrolizumab, is an immunotherapy product that fights cancer with the help of one's own immune system. Immunotherapy is considered a next frontier in cancer treatment.

Keytruda was first approved in 2014 to treat advanced melanoma and has more than 10 approved indications so far. 

The most recent approval for Keytruda was announced in October: first-line treatment of metastatic squamous, non-small cell lung cancer, or NSCLC, in combination with the chemotherapy regimen carboplatin and either paclitaxel or nab-paclitaxel.

Non-squamous NSCLC patients whose tumors do not express EGFR or ALK were the primary driver of Keytruda sales in Q3, Merck executive Adam Schechter said on the earnings call. The drug was approved for the indication in August in combination with pemetrexed and platinum.

Keytruda's sales breakdown by indication were as follows, Schechter said:

  • About 65 percent in NSCLC;
  • 10 percent in melanoma; 
  • 5 percent in head and neck cancer;
  • 5 percent in bladder cancer; 
  • 5 percent in MSI-high;
  • and 10 percent in other indications. 

If Merck maintains its 40-percent long-term share of the U.S. IO market, the franchise would boast a sales potential of $9.4 billion by 2030, CNBC reported, citing BMO Capital Markets analyst Alex Arfaei.

See Also: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates

Other Oncology Drugs

Apart from Keytruda, Merck boasted strong growth in Lynparza, indicated for ovarian and breast cancer, and Lenvima, a tyrosine kinase inhibitor approved for advanced liver cancer, advanced kidney cancer and differentiated thyroid cancer.

Lynparza is being co-developed with AstraZeneca plc (NYSE: AZN) and Lenvima with Japan's Eisai.

The Rest Of The Portfolio 

Merck's vaccine portfolio generated a combined $2.2 billion in sales in Q3, a 13-percent year-over-year increase.

Gardasil has received a shot in the arm following its Chinese launch. The company views the vaccine as possessing a long run rate.

The company's diabetes Januvia and Janumet diabetes franchise saw stable sales in quarter as pricing pressure in the U.S. offset strong demand in markets outside the U.S.

Promising Pipeline

Merck has a rich and deep pipeline of assets in development that hold promise for the future. The company has about 10 late-stage monotherapy and combo therapy candidates for indications ranging from cancer to bacterial infection to cough to heart failure.

mrk.png

Source: Merck

Merck has several supplemental applications under review.

The Stock

Merck shares have fared well so far in 2018 following a modest retreat in 2017.

Citigroup, which has a Buy rating on Merck, recently raised the price target for shares from $79 to $84.

The average analyst price target for Merck is $79.12, according to the Yahoo database.

Photo by Jan Christian/Wikimedia. 

Latest Ratings for MRK

DateFirmActionFromTo
Nov 2018CitigroupMaintainsBuyBuy
Oct 2018CitigroupMaintainsBuyBuy
Oct 2018SunTrust Robinson HumphreyMaintainsBuyBuy

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Alex ArfaeiAnalyst Color Biotech Top Stories Analyst Ratings Movers Media Trading Ideas Best of Benzinga

 

Related Articles (AZN + MRK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
QRVOKeyBancDowngrades0.0
SWKSKeyBancDowngrades0.0
CMAB. Riley FBRDowngrades84.0
COFBairdUpgrades101.0
CORJefferiesDowngrades102.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Crude Plunges With U.S. Supplies Up For 10th Straight Week

Jack In The Box Surges On Sale Rumor